Publications by authors named "Lori Steelman"
Article Synopsis
- Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are aggressive brain tumors, and vorasidenib is a promising oral treatment that targets these mutations and showed preliminary effectiveness.
- A randomized phase 3 trial involved 331 patients with untreated residual or recurrent gliomas, comparing vorasidenib to a placebo over 28-day cycles, focusing on progression-free survival as the main outcome.
- Results indicated that patients taking vorasidenib had significantly longer progression-free survival (27.7 months) compared to those on placebo (11.1 months) and experienced better outcomes before needing further treatment, although adverse effects were more common in the vorasidenib group.
Article Synopsis
- Vorasidenib and ivosidenib are drugs that target mutant forms of isocitrate dehydrogenase (mIDH) and have shown promise in treating recurrent low-grade gliomas (IGG).
- A Phase 1 trial with 49 patients assessed the effectiveness of these drugs by measuring the reduction of D-2-hydroxyglutarate (2-HG), a byproduct of mIDH enzymes, which dropped significantly following treatment.
- Vorasidenib demonstrated better brain penetrance and more consistent 2-HG suppression than ivosidenib, leading to its selection for further Phase 3 testing.
Background: Inhibition of the isocitrate dehydrogenase (IDH)-mutant enzyme is a novel therapeutic target in IDH-mutant gliomas. Imaging biomarkers of IDH inhibitor treatment efficacy in human IDH-mutant gliomas are largely unknown. This study investigated early volumetric, perfusion, and diffusion MRI changes in IDH1-mutant gliomas during IDH inhibitor treatment.
View Article and Find Full Text PDFBackground: Since IDH-mutant (mIDH) low-grade gliomas (LGGs) progress slowly and have a relatively long survival, there is a significant need for earlier measurements of clinical benefit. Guidance using the LGG RANO criteria recommends serial bidirectional (2D) measurements on a single slice; however, questions remain as to whether volumetric (3D) measurements are better, since they would allow for more accurate measurements in irregular shaped lesions and allow readers to better assess areas of subtle change.
Methods: Twenty-one (out of 24) non-enhancing, recurrent mIDH1 LGGs were enrolled in a phase I, multicenter, open-label study of oral ivosidenib (NCT02073994), and with imaging pre- and post-treatment as part of this exploratory ad hoc analysis.
Article Synopsis
- Lower grade gliomas (LGGs) are aggressive brain tumors that often develop resistance to standard therapies, leading to the need for new treatments like vorasidenib, a drug that targets specific mutations in IDH1 and IDH2.
- A phase I clinical trial involving 93 patients with mutant solid tumors, including 52 with glioma, demonstrated that vorasidenib could be taken daily and was generally well tolerated, despite some dose-limiting side effects.
- Results indicated an 18% objective response rate in nonenhancing glioma, with a median progression-free survival of 36.8 months for that group, suggesting that vorasidenib shows promise as a treatment option for recurrent or progressive LGGs
Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7-13.
View Article and Find Full Text PDFPurpose: Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging. Mutations in the isocitrate dehydrogenase 1 () gene occur in most LGGs (> 70%).
View Article and Find Full Text PDFPurpose: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy.
View Article and Find Full Text PDF